Evidence map›Paper›PMID 35400177›Full record

ArticleAntimicrobial agents and chemotherapy2022

Bone Penetration of Cycloserine in Osteoarticular Tuberculosis Patients of China.

Tingting Zhang, Xia Yu, Shu'an Wen, Yi Xue, Hua Xiao, Ruyan Ren, Fen Wang, Lingling Dong, Shibing Qin, Hairong Huang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Tuberculosis of the spine.World journal of orthopedics · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tingting Zhang *National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Xia Yu *National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Shu'an WenNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Yi XueNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Hua XiaoNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Ruyan RenNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Fen WangNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Lingling DongNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Shibing QinDepartment of Orthopedics, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing, China.
Hairong HuangNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospitalgrid.414341.7, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.ORCID 0000-0002-4295-4262
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cycloserine concentrations in plasma and bone that were collected during operations on 28 osteoarticular tuberculosis (TB) patients treated daily with a 500-mg cycloserine-containing regimen were determined. The median concentrations in plasma and bone were 16.29 μg/mL (interquartile range [IQR], 6.47 μg/mL) and 24.33 μg/g (IQR, 14.68 μg/g), respectively. The median bone/plasma penetration ratio was 0.76 (range, 0.33 to 1.98). Cycloserine could effectively penetrate bone and acquire concentrations comparable to those in plasma, which favors its usage in osteoarticular TB treatment.

Indexed as

Tuberculosis, Multidrug-ResistantTuberculosis, OsteoarticularAntitubercular AgentsChinaCycloserineHumansAntitubercular AgentsCycloserinebonecycloserinedrug penetrationosteoarticular tuberculosisplasma

Identifiers

PMID35400177
PMCPMC9112879
OpenAlexW4223538074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.